



28th March, 2026

The Listing Department
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor, Plot No. C/1
G Block, Bandra-Kurla Complex, Bandra (E)
Mumbai — 400051
Scrip Symbol: CURIS

Dear Sir/Madam,

Subject: Intimation under Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 (“LODR Regulations”)

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we wish to inform that, the Board of Directors of the Company at its meeting held on Saturday, 28th March 2026 has inter-alia, approved the following:

- a) Curis Lifesciences Limited (the Company) has agreed to make a strategic investment in Uninova Lifesciences Private Limited ("the Shares to Investee Company") by acquiring and/or subscribing to equity shares equivalent to 51% of the issued and paid-up share capital of the Investee Company. By acquiring these shares Uninova Lifesciences Private Limited shall become the subsidiary company of M/s. Curis Lifesciences Limited. The Sellers have agreed to sell and transfer the equity shares at a Purchase Consideration of INR 20,65,500. The definitive Share Purchase Agreement is finalized and is formally executed.

The details required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI LODR Regulations”) read with the SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015 is enclosed as Annexure I.

- b) According to the provisions of Section 138 of the Companies Act, 2013, read with Rule 13 of the Companies (Accounts) Rules, 2014, the Board of Directors has appointed M/s NGST & Associates, Chartered Accountants, as the Internal Auditors of the Company for the Financial Year 2025-26.

The details required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI LODR Regulations”) read with the SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015 is enclosed as Annexure II.

- c) According to the provisions of Section 204 of the Companies Act, 2013, read with Rule 9 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, the Board of Directors has appointed M/s. Sachin Thakkar and Associates, Company Secretaries, Peer Reviewed Audit firm as the Secretarial Auditors of the Company for the Financial Year 2025-26.



Curis *Lifesciences Ltd.*

The details required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR Regulations") read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, are enclosed as Annexure III.

Thanking you,
Yours Faithfully

FOR CURIS LIFESCIENCES LIMITED

JAIMIK MANSUKHLAL PATEL
WHOLE-TIME DIRECTOR
DIN: 07371003



Annexure I

Information as required under Regulation 30 - Part A of Para A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015

Sr. No.	Particulars	
1.	Name of the target entity, details in brief such as size and turnover.	<p>Name: M/s Uninova Lifesciences Private Limited ("Target Company") ("Uninova")</p> <p>CIN: U24290GJ2021PTC126583</p> <p>Registered Office: C/121/A, First Floor, Sagar Estate-2, behind Sukhsagar Hotel, Sanand Cross Road, Sarkhej, Ahmedabad, Daskroi, Gujarat, India, 382210</p> <p>Authorised Share Capital: INR 30,00,000 Paid-up Share Capital: INR 30,00,000</p> <p>Audited Turnover of Uninova for the Financial year 2024-25 is INR 5.39 crores.</p>
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length";	<p>The acquisition doesn't fall within the purview of related party transactions.</p> <p>None of the promoter/ promoter group/ group companies of listed entity have any interest in the entity being acquired.</p>
3.	Industry to which the entity being acquired belongs	The target company is engaged into the business of manufacturing and trading of pharmaceutical products
4.	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity).	<p>This acquisition aligns with the Company's strategic growth initiatives aimed at business expansion, diversification and strengthening of its market presence in the pharmaceutical industry.</p> <p>For acquiring 51% shareholding, Curis Lifesciences Limited ("Curis") has entered into a Share Purchase Agreement ("SPA") with the Promoters cum Shareholders of the target company who holds the entire 100% stake in the company.</p> <p>The remaining 49% shareholding will continue to be held by the existing promoters of the Target Company.</p>



		Post-acquisition of 51% stake, the Target Company will become a subsidiary of the Company.								
5.	Brief details of any governmental or regulatory approvals required for the acquisition	No governmental or regulatory approvals are required for the acquisition.								
6.	Indicative time period for completion of the acquisition	The acquisition will be completed within 30 days from date of execution of Share Purchase Agreement, subject to the fulfilment of the conditions as per SPA.								
7.	Nature of consideration – whether cash consideration or share swap and details of the same.	Cash Consideration								
8.	Cost of acquisition or the price at which the shares are acquired.	The acquisition is being undertaken for a total Purchase consideration of INR 20,65,500/- (Rupees Twenty Lakhs Sixty Five Thousand and Five Hundred Only).								
9.	Percentage of shareholding /Control acquired and / or number of shares acquired.	Acquisition of 51% of Equity Share capital of the target company. The company shall acquire 1,53,000 shares (in number) of the Target Company.								
10.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, and history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief).	<p>M/s. Uninova Lifesciences Private Limited CIN: U24290GJ2021PTC126583 is a Private company incorporated on 22nd October, 2021 under the provisions of the Companies Act, 2013, and engaged into the business of manufacturing and trading of pharmaceutical products in inter alia Organic therapeutic chemicals, Medicines of all types of and Healthcare Products under the brand name of “Uninova.”</p> <p>The company primarily sells its products in India.</p> <p>The turnover of the investee company for the last three financial years are as follows:</p> <table border="1"><thead><tr><th>Years</th><th>Turnover (INR Crores)</th></tr></thead><tbody><tr><td>FY 2024-25</td><td>5.39</td></tr><tr><td>FY 2023-24</td><td>5.11</td></tr><tr><td>FY 2022-23</td><td>2.90</td></tr></tbody></table>	Years	Turnover (INR Crores)	FY 2024-25	5.39	FY 2023-24	5.11	FY 2022-23	2.90
Years	Turnover (INR Crores)									
FY 2024-25	5.39									
FY 2023-24	5.11									
FY 2022-23	2.90									



Annexure – II

Information as required under Regulation 30 - Part A of Para A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015

Sr no.	Particulars	Description
1.	Reason for change viz. appointment, resignation, Cessation, removal, death or otherwise	The appointment is made to ensure mandatory compliance with Section 138 of the Companies Act, 2013, and to strengthen the organization's Internal Financial Controls.
2.	Date of appointment/ cessation (as applicable)	March 28, 2026
3.	Term of appointment	Appointed as an Internal Auditor of the Company for conducting internal audit for the Financial Year 2025-26.
4.	Brief profile (in case of appointment)	NGST & Associates is a Mumbai-based Chartered Accountancy firm established in 2012 that provides comprehensive auditing, accounting, and taxation services. The firm offers services to a diverse range of clients, including small, medium, and public listed companies, with a focus on statutory audits, internal audits, and transaction advisory.
5.	Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable



Annexure – III

Information as required under Regulation 30 - Part A of Para A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015

Sr no.	Particulars	Description
1.	Reason for change viz. appointment, resignation, Cessation, removal, death or otherwise	Appointment is made to comply with the mandatory statutory requirements of Section 204 of the Companies Act, 2013, and to ensure robust corporate governance and legal compliance.
2.	Date of appointment/ cessation (as applicable)	March 28, 2026
3.	Term of appointment	Appointed as the Secretarial Auditor of the Company to conduct the Secretarial Audit for the Financial Year 2025-26.
4.	Brief profile (in case of appointment)	Sachin Thakkar and Associates is a peer-reviewed firm of practicing Company Secretaries based in Ahmedabad Gujarat. The firm is led by CS Sachin Thakkar, a Fellow Member of the ICSI with over a decade of expertise in secretarial compliances, legal affairs, insolvency proceedings, and regulatory representations before the NCLT, Regional Director (RD), and ROC. The firm specializes in corporate laws, SEBI compliances, SME IPOs, and regulatory representations before the ROC and NCLT.
5.	Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable